TREACE MEDICAL CONCEPTS, INC. Income Statement
TMCI|5 years of annual SEC 10-K data (FY2021-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 5 fiscal years. All figures from audited SEC 10-K filings.
TREACE MEDICAL CONCEPTS, INC. reported $187M in revenue and $50M in net loss for FY2025. Revenue has grown at a 47.6% compound annual rate over the past 4 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 1.13 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $187.1M | $141.8M | $94.4M | $57.4M | $39.4M |
| Cost of Revenue | $35.2M | $25.5M | $16.9M | $12.5M | $7.6M |
| Gross Profit | $151.9M | $116.3M | $77.5M | $44.9M | $31.8M |
| SG&A Expense | $47.0M | $33.0M | $18.4M | $6.5M | $4.5M |
| R&D Expense | $15.4M | $13.6M | $10.2M | $5.8M | $5.1M |
| Operating Income | -$51.4M | -$34.8M | -$16.5M | $855.0K | -$3.5M |
| Interest Expense | $5.2M | $4.4M | $4.1M | $2.8M | $841.0K |
| Income Tax | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$49.5M | -$42.8M | -$20.6M | -$3.7M | -$4.3M |
| EPS (Basic) | -$0.81 | -$0.77 | -$0.43 | -$0.12 | - |
| EPS (Diluted) | -$0.81 | -$0.77 | -$0.43 | -$0.12 | -$0.13 |
| Shares Outstanding | 60.9M | 55.3M | 55.6M | 54.2M | 36.9M |
| Gross Margin | 81.2% | 82.0% | 82.1% | 78.3% | 80.6% |
| Operating Margin | -27.5% | -24.6% | -17.5% | 1.5% | -9.0% |
| Profit Margin | -26.5% | -30.2% | -21.8% | -6.4% | -10.8% |